Kanghule tells you what the efficacy and function of raloxifene tablets are

The efficacy and role of raloxifene are: Raloxifene is a benthiophene compound, a new concept non-hormonal drug that resists bone resorption, and is a second-generation selective estrogen receptor modulator (SERM). SERMs can act as estrogen agonists or antagonists. Raloxifene has an estrogen agonistic effect on the bones and cardiovascular system, and an estrogen antagonistic effect on the breast and uterus without many adverse reactions of estrogen. It can increase bone mineral density and prevent postmenopausal bone loss; it reduces total cholesterol, low-density lipoprotein cholesterol (LDL-C), fibrinogen and lipoprotein A levels, without affecting triglycerides and high-density lipoprotein cholesterol (HDL-C); it does not stimulate the breast and endometrium, and does not increase the risk of breast cancer and endometrial cancer.

Raloxifene is a second-generation SERM that was approved by the U.S. Food and Drug Administration for the treatment of osteoporosis in postmenopausal women in 1997 and was approved for the treatment of osteoporosis in October 1999. Many animal studies and clinical trials in the past have proven that raloxifene exhibits estrogen agonistic effects on bones and cardiovascular systems and estrogen antagonistic effects on the uterus and breast. It can be used to prevent and treat osteoporosis in postmenopausal women, improve menopausal symptoms in postmenopausal women, and has potential cardiovascular protective effects.

Raloxifene is called a "selective estrogen receptor modulator" by the medical community. In layman's terms, the so-called "selective estrogen receptor modulator" means that it has a stimulating effect on the estrogen receptors of some tissues or organs (such as bones), while it has an inhibitory effect on the estrogen receptors of other tissues or organs (such as the breast and uterus).

The MORE trial selected 7705 postmenopausal women with osteoporosis and followed them for 48 months. The trial results confirmed that taking raloxifene can significantly reduce the risk of vertebral fractures. After taking raloxifene for 1 year, the risk of vertebral fractures dropped by 68%; after taking raloxifene for 4 years, the risk of vertebral fractures dropped by 50%. According to the MORE study, the relative risk of breast cancer in raloxifene users was 70% lower than that in the control group.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: